Back Menu
id опорной категории = 2
id текущей категории = 1
id родительской категории = 1

News

HSCI Announces 1H 2020 Consolidated Results under IFRS 07.09.2020

Moscow – 7 September, 2020. PJSC “HSCI” – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced its reviewed consolidated interim results for the first half of 2020 in accordance with the International…

Read More
HSCI Registered New Test Systems for Detecting Immunity to COVID-19 02.09.2020

“NextGen” Co. Ltd., a Skolkovo resident and a subsidiary of Human Stem Cells Institute, has received Registration Certificates for the new SARS-CoV-2-CoronaPass test systems for detecting total antibodies to the coronavirus. The test system developed by NextGen with the support…

Read More
GENETICO Listed Bonds on the Moscow Exchange 20.06.2020

On June 29, 2020, GENETICO LLC (Center of Genetics and Reproductive Medicine GENETICO, hereinafter –– “GENETICO” or “the Genetico Center”), HSCI’s subsidiary, completed its offering of 5-year bonds on the Moscow Exchange. 145,000 securities with a face value of 1,000…

Read More
Skolkovo Town Planning Board Approved Project of HSCI’s Laboratory and Production Complex 29.05.2020

The Skolkovo Foundation Town Planning Board has approved the concept and preliminary design of the laboratory and production complex to be built by Human Stem Cells Institute on the premises of the Skolkovo Innovation Center. According to the project, a…

Read More
Mount-Sinai Gives Rights to Develop Test Systems for Antibodies to SARS-CoV-2 to Russian GENETICO 22.04.2020

GENETICO LLC (Center of Genetics and Reproductive Medicine GENETICO, hereinafter – “Genetico Center”), HSCI’s subsidiary, has concluded a license agreement with the Mount Sinai hospital (Icahn School of Medicine at Mount Sinai) for the right to use a highly specific…

Read More
The World’s First Gene-Activated Material Became Available for Russian Healthcare 13.04.2020

In April 2020, the world’s first gene-activated material for bone tissue regeneration became available for the Russian healthcare. Registration certificate No. RZN 2019/8310 of April 23, 2019. The gene-activated bone substitute, marketed as Histograft, is based on octacalcium phosphate (OCP)…

Read More
NextGen Started Phase II Clinical Trials of a Gene Therapy Drug for Diabetic Foot Syndrome 21.11.2019

“NextGen” Co. Ltd., HSCI’s subsidiary and a Skolkovo resident, announces the start of Phase II clinical trials of a gene therapy drug for Diabetic Foot Syndrome (DFS). The protocol and design of the placebo-controlled, multicenter, randomized clinical trials were approved…

Read More
HSCI Announces 1H2018Consolidated Results under IFRS 29.08.2018

Moscow – 29 August, 2018. PJSC “HSCI”–The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced its reviewedconsolidated interim results for the first half of 2017in accordance with the International Financial Reporting Standards (IFRS)….

Read More
HSCI Announces 2017 Consolidated Results under IFRS 03.05.2018

HSCI Announces 2017 Consolidated Results under IFRS Moscow – 03 may, 2018.   PJSC “HSCI” – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced its audited consolidated results for 2017 in accordance with…

Read More
HSCI Announces 2018 Consolidated Results under IFRS 30.04.2018

Moscow — 30 April, 2019. PJSC “HSCI” — The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced its audited consolidated results for 2018 in accordance with the International Financial Reporting Standards (IFRS). In…

Read More